These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25317804)

  • 41. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.
    Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G
    Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
    Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
    Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
    J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.
    Schreuer MS; Chevolet IL; Jansen YJ; Seremet TC; Wilgenhof S; Liénard D; Del Marmol V; Neyns B
    Melanoma Res; 2015 Feb; 25(1):68-74. PubMed ID: 25396684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma.
    Moser JC; Pulido JS; Dronca RS; McWilliams RR; Markovic SN; Mansfield AS
    Melanoma Res; 2015 Feb; 25(1):59-63. PubMed ID: 25396683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trastuzumab-induced cardiotoxicity: is it a personalized risk?
    Milano GA; Serres E; Ferrero JM; Ciccolini J
    Curr Drug Targets; 2014; 15(13):1200-4. PubMed ID: 25395105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.
    Katsurada K; Ichida M; Sakuragi M; Takehara M; Hozumi Y; Kario K
    Springerplus; 2014; 3():620. PubMed ID: 25392790
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
    Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
    Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunity to the vacuolar ATPase complex accessory unit ATP6S1 in patients with malignant melanoma.
    Zhou J; Gupta M; Wu X; Yoon C; Giobbie-Hurder A; Hodi FS
    Cancer Immunol Res; 2015 Jan; 3(1):59-67. PubMed ID: 25387894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.
    Mortimer J; Jung J; Yuan Y; Kruper L; Stewart D; Chung S; Yu KW; Mendelsohn M; D'Apuzzo M; Tegtmeier B; Dadwal S
    Breast Cancer Res Treat; 2014 Dec; 148(3):563-70. PubMed ID: 25385180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country.
    Chicaíza-Becerra L; García-Molina M; Gamboa O; Castañeda-Orjuela C
    Rev Salud Publica (Bogota); 2014; 16(2):270-80. PubMed ID: 25383500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab for symptomatic radiation-induced tumor enlargement in pediatric low grade gliomas.
    Foster KA; Ares WJ; Pollack IF; Jakacki RI
    Pediatr Blood Cancer; 2015 Feb; 62(2):240-245. PubMed ID: 25382690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib.
    Kanaji N; Tadokoro A; Watanabe N; Inoue T; Ishii T; Dobashi H; Bandoh S
    Am J Case Rep; 2014 Nov; 15():480-4. PubMed ID: 25380070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.
    Badulescu F; Badulescu A; Paul D; Popescu CF; Florescu C
    Onco Targets Ther; 2014; 7():1911-7. PubMed ID: 25378932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
    Niravath P; Tham YL; Wang T; Rodriguez A; Foreman C; Hilsenbeck SG; Elledge R; Rimawi M
    Oncologist; 2015 Jan; 20(1):13. PubMed ID: 25378456
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
    Falchook GS; Wheler JJ; Naing A; Jackson EF; Janku F; Hong D; Ng CS; Tannir NM; Lawhorn KN; Huang M; Angelo LS; Vishwamitra D; Hess K; Howard AN; Parkhurst KL; Amin HM; Kurzrock R
    Oncotarget; 2014 Nov; 5(21):10280-92. PubMed ID: 25373733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Axitinib in metastatic renal carcinomas: update of knowledge about side effects].
    Albiges L; Izzedine H; Ederhy S; Robert C; Gravis G; Boyle H; Scotté F; Hartl D; Escudier B
    Bull Cancer; 2014 Oct; 101(10):976-88. PubMed ID: 25373697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.
    Witzel I; Müller V; Abenhardt W; Kaufmann M; Schoenegg W; Schneeweis A; Jänicke F
    BMC Cancer; 2014 Nov; 14():806. PubMed ID: 25371387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).
    Uppal H; Doudement E; Mahapatra K; Darbonne WC; Bumbaca D; Shen BQ; Du X; Saad O; Bowles K; Olsen S; Lewis Phillips GD; Hartley D; Sliwkowski MX; Girish S; Dambach D; Ramakrishnan V
    Clin Cancer Res; 2015 Jan; 21(1):123-33. PubMed ID: 25370470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Ring A; Wheatley D; Hatcher H; Laing R; Plummer R; Uttenreuther-Fischer M; Temple G; Pelling K; Schnell D
    Clin Cancer Res; 2015 Jun; 21(12):2737-44. PubMed ID: 25370464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.